Acute Kidney Injury, Fluid Overload, Ultrasonography
Conditions
Keywords
Point-Of-Care ultrasound, Doppler, Major adverse kidney events, Portal flow pulsatility, IVC ultrasound, Cardiac ultrasound, Right ventricular failure, Intensive care
Brief summary
Fluid overload is associated with adverse outcomes in patients with severe acute kidney injury. It remains unclear if fluid overload is merely a marker of disease severity or if organ congestion is a mediator of complications. Point-of-care ultrasound could be a modality used to assess organ congestion and its clinical implications. The objective of this study is to determine whether ultrasound markers of organ congestion are associated with major adverse kidney events in critically ill patients with severe acute kidney injury.
Detailed description
Background: Fluid overload is associated with adverse outcomes in patients with severe acute kidney injury. It remains unclear if fluid overload is merely a marker of disease severity or if organ congestion is a direct mediator of complications. Point-of-care ultrasound could be a modality used to assess organ congestion and its clinical implications. Objective: To determine whether ultrasound markers of organ congestions are associated with major adverse kidney events and other adverse clinical outcomes. Study design: A cohort of critically ill patients with a new onset of severe acute kidney injury will undergo repeated ultrasound assessments to detect the presence of the following markers: * Portal flow pulsatility on pulse-wave Doppler * Discontinuous intra-renal venous flow on pulse-wave Doppler * Abnormal hepatic vein waveform on pulse wave Doppler * Presence of pulmonary B-line artifacts on 2D lung ultrasound * Presence of dilated and non-collapsible inferior vena cava on 2D ultrasound * Presence of systolic right ventricular dysfunction * Presence of systolic left ventricular dysfunction Clinical outcomes will be collected for up to 90 days after recruitment. Perspective: An approach targeting the resolution of organ congestion might improve the prognosis in patients with severe acute kidney injury. Identifying clinically relevant markers of organ congestion is a precursor to the design of future interventional trials investigating personalized fluid balance management.
Interventions
DIAGNOSTIC_TESTPortal vein flow
Doppler assessment performed on day 0, 3 and 7.
DIAGNOSTIC_TESTIntra-renal flow
Doppler assessment performed on day 0, 3 and 7.
DIAGNOSTIC_TESTHepatic vein flow
Doppler assessment performed on day 0, 3 and 7.
DIAGNOSTIC_TESTPulmonary B-lines
Ultrasound assessment of performed on day 0, 3 and 7.
DIAGNOSTIC_TESTDimensions of the inferior vena cava
Ultrasound assessment of performed on day 0, 3 and 7.
DIAGNOSTIC_TESTLeft ventricular function
Ultrasound assessment of performed on day 0, 3 and 7.
DIAGNOSTIC_TESTRight ventricular function
Ultrasound assessment of performed on day 0, 3 and 7.
Sponsors
Unity Health Toronto
Sunnybrook Health Sciences Centre
University of Kentucky
University of Alberta
Montreal Heart Institute
Centre hospitalier de l'Université de Montréal (CHUM)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Admitted to the ICU * Women with serum creatinine ≥ 100 µmol/L and men with serum creatinine ≥ 130 µmol/L * Severe acute kidney injury (AKI) defined either: A ≥ 2-fold increase in serum creatinine from a known pre-morbid baseline or during the current hospitalization OR achievement of a serum creatinine ≥ 354 µmol/L with evidence of a minimum increase of 27 µmol/L from pre-morbid baseline or during the current hospitalization OR Urine output \< 6.0 mL/kg over the preceding 12 hours OR initiation of renal replacement therapy (RRT) for severe AKI initiated less than 72 hours before recruitment.
Exclusion criteria
* Lack of commitment to provide RRT as part of limitation of ongoing life support. (Operational definition: Critical care team has deemed the patient not to be eligible for escalation of life support, including the initiation of RRT, or substitute decision makers have declined offer of same.) * Known pre-hospitalization advanced chronic kidney disease, defined by an estimated glomerular filtration rate \< 20 mL/min/1.73 m2 in a patient who is not on chronic RRT. (Operational definition: The coordinator will review all documented serum creatinine values within 365 days prior to the date of admission for the current hospitalization. The value closest to the admission date will be considered as the baseline and will be used to calculate the corresponding estimated glomerular filtration rate using an online calculator. A value of \< 20 mL/min/1.73 m2 derived from the CKD-EPI equation will be grounds for exclusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with major adverse kidney events at 30 days | 30 days | Either death, receipt of renal replacement therapy or sustained loss of kidney function (new onset of estimated glomerular filtration rate (eGFR) \< 60 or, if pre-existing eGFR \< 60, 25% or greater decline in eGFR) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with renal replacement therapy dependence at 30 days | 30 days | Receipt of renal replacement therapy at 30 days from enrollment |
| Number of participants with sustained loss of kidney function at 30 days | 30 days | New onset of estimated glomerular filtration rate (eGFR) \< 60 or, if pre-existing eGFR \< 60, 25% or greater decline in eGFR) |
| Ventilation-free days through day 30 | 30 days | A ventilator-free day will be defined as the receipt of \< 2 hours of either invasive or non-invasive ventilation within a 24-hour period. |
| Intensive care unit (ICU)-free days through day 30 | 30 days | An ICU-free day will be defined as admission to an ICU for \< 2 hours within a 24 hours period. |
| Rate of in-hospital death | 30 days | All cause mortality during hospital stay |
| Number of participants with major adverse kidney events at 90 days | 90 days | Either death, receipt of renal replacement therapy or sustained loss of kidney function (estimated glomerular filtration rate (eGFR) \< 60 or, if pre-existing eGFR \< 60, 25% or greater decline in eGFR) |
| Rate of death at 90 days | 90 days | All cause mortality at 90 days |
| Estimated glomerular filtration rate at 90 days | 90 days | Calculated with the CKD-EPI equation (92) with serum creatinine from a sample drawn as close as possible to Day 90. |
| Vasopressor-free days though day 30 | 30 days | Vasopressor will include norepinephrine, epinephrine, vasopressin and phenylephrin |
Other
| Measure | Time frame | Description |
|---|---|---|
| Hemodynamic instability during renal replacement therapy | 7 days | Intradialytic hypotension (MAP\<65 mmHg) requiring one or more of the following interventions: interruption of fluid removal, introduction of norepinephrine or increase in its dose of more than 25%, administration of volume expansion or interruption of RRT within 8 hours after initiating net negative fluid balance. |
Countries
Canada, United States
Outcome results
None listed